Abstract
Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 205-218 |
| Number of pages | 14 |
| Journal | CNS and Neurological Disorders - Drug Targets |
| Volume | 5 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 1 2006 |
| Externally published | Yes |
Keywords
- Antipsychotic drug
- Neuromedin N
- Peptide
- Schizophrenia
- Xenin
ASJC Scopus subject areas
- Neuroscience(all)
- Pharmacology